What is Inhibrx?
Inhibrx Biosciences, Inc. operates as a specialized clinical-stage biopharmaceutical entity headquartered in La Jolla, California. The organization focuses on the research and development of advanced biologic therapeutics, specifically utilizing tetravalent and hexavalent single-domain antibody (sdAb) platforms. Its primary clinical assets, including INBRX-109 and INBRX-106, are currently undergoing rigorous phase 2 clinical trials. These candidates target high-unmet-need indications such as unresectable chondrosarcoma, non-small cell lung cancer, and various solid tumors. By positioning itself at the intersection of oncology and immunology, Inhibrx maintains a robust competitive advantage in the development of next-generation protein therapeutics designed to improve patient outcomes in challenging disease environments.
How much funding has Inhibrx raised?
Inhibrx has raised a total of $21M across 2 funding rounds:
Debt
$20M
Debt
$1M
Debt (2015): $20M with participation from Oxford Finance
Debt (2020): $1M led by PPP
Key Investors in Inhibrx
Oxford Finance
Oxford Finance is a specialty finance firm that provides flexible debt solutions tailored to the unique capital requirements of healthcare and life sciences organizations.
PPP
Public-Private Partnership
What's next for Inhibrx?
With the recent influx of capital, Inhibrx is well-positioned to accelerate its phase 2 clinical programs and expand its research infrastructure. The strategic focus remains on achieving critical data milestones for its lead candidates, which will likely serve as the foundation for future regulatory filings and potential commercialization partnerships. As the company matures, the emphasis will shift toward optimizing manufacturing processes and scaling clinical operations to support broader patient access. Investors and industry stakeholders are closely monitoring the progression of these trials, as successful clinical validation could significantly enhance the company's valuation and solidify its standing as a leader in the biopharmaceutical sector. The firm's ability to maintain its research momentum while managing the inherent risks of drug development will be the primary determinant of its long-term growth trajectory.
See full Inhibrx company page
